Stockreport

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion [Yahoo! Finance]

Oragenics Inc.  (OGEN) 
NASDAQ:AMEX Investor Relations: ir.oragenics.com
PDF for the treatment of neurological disorders, today announced it has appointed Dr. James "Jim" Kelly, Neurologist, as its Chief Medical Officer, to oversee its upcoming P [Read more]